{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:49Z","timestamp":1790931349577,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00259-026-08037-4","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:45:39Z","timestamp":1783395939000},"page":"6977-6987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort"],"prefix":"10.1007","volume":"53","author":[{"given":"Muammer","family":"Misirci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Khreish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Burgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Blickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz B.","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Speicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Petto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schaefer-Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-3375","authenticated-orcid":false,"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"8037_CR1","unstructured":"Research C. for DE and. FDA approves Pluvicto for metastatic castration-resistant prostate cancer. FDA. FDA. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. Accessed 16 June 2025."},{"key":"8037_CR2","unstructured":"Pluvicto European Medicines Agency (EMA). 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pluvicto. Accessed 16 June 2025."},{"key":"8037_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"8037_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25:99\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(23)00529-6.","journal-title":"Lancet Oncol"},{"key":"8037_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"8037_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"key":"8037_CR7","unstructured":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group. TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer (ANZUP protocol 1603). clinicaltrials.gov; 2022 June. Report No.: NCT03392428. https:\/\/clinicaltrials.gov\/study\/NCT03392428. Accessed 12 June 2025."},{"key":"8037_CR8","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","volume":"65","author":"V Murthy","year":"2024","unstructured":"Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, et al. Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with Phase 3 VISION data. J Nucl Med. 2024;65:1740\u20134. https:\/\/doi.org\/10.2967\/jnumed.124.267816.","journal-title":"J Nucl Med"},{"key":"8037_CR9","unstructured":"Endocyte VISION. June : an international, prospective, open label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive psma-positive metastatic castration-resistant prostate cancer (mCRPC). clinicaltrials.gov; 2024 Dec. Report No.: NCT03511664. https:\/\/clinicaltrials.gov\/study\/NCT03511664. Accessed 12 2025."},{"key":"8037_CR10","unstructured":"ANZCTR - Registration. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12615000912583. Accessed 12 June 2025."},{"key":"8037_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07125-1","author":"E Topal","year":"2025","unstructured":"Topal E, Kovan B, \u0130ribas A, Kuyumcu S, Basaran M, Mal\u00e7ok Demirta\u015f A, et al. Impact of extended [177Lu]Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued? Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07125-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8037_CR12","unstructured":"Ezziddin SREALITY, Study. June : Analysis of a prospective registry to assess outcome and toxicity of targeted radionuclide therapy in patients with mCRPC in clinical routine. clinicaltrials.gov. 2022 Dec. Report No.: NCT04833517. https:\/\/clinicaltrials.gov\/study\/NCT04833517. Accessed 12 2025."},{"key":"8037_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","volume":"49","author":"F Khreish","year":"2022","unstructured":"Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. 177Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49:1075\u201385. https:\/\/doi.org\/10.1007\/s00259-021-05525-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8037_CR14","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8037_CR15","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"8037_CR16","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1002\/cam4.4125","volume":"10","author":"EM Al-Ezzi","year":"2021","unstructured":"Al-Ezzi EM, Alqaisi HA, Iafolla MAJ, Wang L, Sridhar SS, Sacher AG, et al. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. Cancer Med. 2021;10:5775\u201382. https:\/\/doi.org\/10.1002\/cam4.4125.","journal-title":"Cancer Med"},{"key":"8037_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00345-018-2574-2","volume":"38","author":"M Pinart","year":"2020","unstructured":"Pinart M, Kunath F, Lieb V, Tsaur I, Wullich B, Schmidt S, et al. Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review. World J Urol. 2020;38:613\u201335. https:\/\/doi.org\/10.1007\/s00345-018-2574-2.","journal-title":"World J Urol"},{"key":"8037_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1213755.","journal-title":"N Engl J Med"},{"key":"8037_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","volume":"85","author":"KN Chi","year":"2024","unstructured":"Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, et al. Safety analyses of the Phase 3 VISION trial of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur Urol. 2024;85:382\u201391. https:\/\/doi.org\/10.1016\/j.eururo.2023.12.004.","journal-title":"Eur Urol"},{"key":"8037_CR20","doi-asserted-by":"publisher","first-page":"e2433863","DOI":"10.1001\/jamanetworkopen.2024.33863","volume":"7","author":"YY Soon","year":"2024","unstructured":"Soon YY, Marschner IC, Schou M, Hofman MS, Emmett L, Davis ID, et al. Lu-177 PSMA vs Comparator treatments and survival in metastatic castration-resistant prostate cancer. JAMA Netw Open. 2024;7:e2433863. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.33863.","journal-title":"JAMA Netw Open"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08037-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08037-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08037-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:18Z","timestamp":1790929938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08037-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8037"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08037-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study was approved by the Institutional Review Board of \u00c4rztekammer des Saarlandes\/Saarbr\u00fccken (ethics committee permission number 140\/17). Informed consent was obtained from all patients for being included in the study.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study, after being comprehensively informed about potential risks and adverse events of the treatment.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants agreed to the publication of any resulting data in anonymized form.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has conflicts of interest to declare and no sources of funding were used.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}